- 6 dental technology updates in May
- From clinician to leader: Building confidence, capability and leadership in dentistry
- Operationalizing AI at scale: A practical framework for enterprise-scale success
- 3 key stats on the orthodontist workforce
- Meet the COOs of 10 specialty DSOs
- Data, cross-training, and pipeline development: How health systems are rethinking OR staffing
- How top health systems are redefining the digital patient experience
- ‘The most significant change in 20 years’: Cancer centers prepare for daraxonrasib demand
- A Smooth Handoff From Decision to Dollars: Connecting the Last Mile in Healthcare Payments
- Budget-Strapped Montana Will Stress-Test Trump’s Medicaid Work Rules
- How CEOs actually use hospital rankings — and when they don’t
- What OU Health’s founding CEO learned building a new health system
- Arkansas hospital CEO to step down after 11 years for new role
- The behavioral health workforce pipeline: Where it stands and where it’s headed
- 6 major investments in youth behavioral health
- Coalition for Health AI unveils governance playbook for systems
- 66 health systems ranked by long-term debt
- UnitedHealthcare drops some prior auth requirements for cardiology, orthopedic services
- 8 No Surprises Act shake-ups physicians need to know
- The ASC independence playbook: 3 leaders’ thoughts
- Dr. Rahimah Maina opens new dental practice
- GWU offloaded its $450M physician group problem — why the industry watching
- The gastroenterologist pay gap
- Texas surgery center to double in size, add 2 ORs
- What dental leaders told us in May
- Climate Change: Statement on Proposed Rescission of Climate-Related Disclosure Rules
- Kenyan Court Blocks Trump's Plan To Quarantine Ebola Patients
- What’s going on at the FTC? 3 notes for ASC leaders
- 8 DSOs making headlines
- The physician noncompete battle in 5 key figures
- The physician red flags that can predict a bad ASC partner
- Patient death draws renewed CMS scrutiny at HCA’s Mission Hospital
- Nearly 70% of US counties lack a GI: 13 concerning workforce stats
- Statement of Commissioner Mark T. Uyeda on the Rescission of Climate-Related Disclosure Rules
- A new behavioral health profession is born
- Keynote Remarks at the 2026 Reagan National Economic Forum
- Statement on Proposing Release for Rescission of Climate-Related Disclosure Rules
- Dentists’ pay climbed the most in these 10 states
- Mental Health Disorders Now No. 1 Cause of Disability Worldwide
- Massachusetts AG sues UnitedHealthcare over alleged Medicaid fraud
- UnitedHealthcare to nix nearly two thirds of pediatric prior auths
- Industry Voices—Patients are building a new healthcare system. The industry is finally catching up
- Weekly Rundown—Moffitt Cancer Center expands Reimagine Care's virtual oncology model; Tanner Health deploys AI workforce solution
- Study: LA Canine Outbreak Caused By Low Vaccination Rates, Crowded Boarding
- Ocrelizumab Effective In Slowing Progressive MS, Trial Shows
- Long COVID Might Be Twice As Common As Previously Thought
- In Vaccine-Skeptical California County, A Potential Playbook To Contain Measles
- Heavy Drinking Harms College Students' Brain Power, Study Finds
- After Her Bout of Amnesia, a $59,000 Billing Dispute Wouldn’t Go Away
- A Trump Stronghold Grapples With Health Risks of ICE Detention Sites
- Pharma urged to modernize patient support as young adult cancer rates rise
- Philips adds a spoonful of Disney sugar to ease kids’ MRI anxieties
- MannKind seeks long-awaited sales boost with inhaled insulin approval for kids
- Aetna to launch ‘on demand’ virtual mental health services in 2027
- U of Connecticut dental school reappoints dean for 2nd term
- Michigan dentist charged with Medicaid fraud
- Brand-name drug prices climb after launch in US, fall abroad amid MFN push: report
- ASCO: After Takeda’s defeat, Dizal picks up baton to take on J&J in EGFR lung cancer subtype
- Acadia in the headlines: 6 things to know
- 26 behavioral health executive moves to know
- AstraZeneca gains 2nd bladder cancer nod in key expansion for Imfinzi
- Advocate Health grows Q1 revenue by 10.8% amid higher volumes, greater efficiency
- Behavioral health hospital operator to pay $32M in Medicare fraud settlement
- Bangladesh Measles Surge Kills 500+ Children; Vaccine Delays Blamed
- Care navigation startup Garner Health banks $100M series E at $2.74B valuation
- HCA bolsters workforce pipeline with healthcare professional college acquisition
- Plant-Based Diet May Cut Obesity Risk For Women In Menopause
- Pharma leaders meet with PM Takaichi in push for Japan to retain R&D edge
- Penn Medicine, K Health partner to deploy AI clinical agents
- CVS restores coverage of Eli Lilly obesity med Zepbound, adds new pill Foundayo
- CVS restores coverage of Eli Lilly obesity med Zepbound, adds new pill Foundayo
- CMS finalizes changes to No Surprises Act dispute resolution process
- Smartwatch App Accurately Detects Major Epileptic Seizures
- Racial Gap Exists For Asthma Inhaler Use
- New Colon Cancer Screening Guidelines Add Blood And At-Home Tests
- Fierce Pharma Asia—More China biotech hawkishness; Pfizer’s $10B Innovent deal; Astellas’ roadmap
- CVS expands partnership with Salesforce for greater call center personalization
- Nurse Convicted In Patient's Death Turns Fatal Drug Error Into Cautionary Tale
- Wearable Ultrasound Patch Monitors High-Risk Pregnancies In Real Time
- In a Vaccine-Skeptical California County, a Potential Playbook To Contain Measles
- Listen to the Latest ‘KFF Health News Minute’
- Teladoc Health inks partnership with Walmart to expand virtual care services
- PharmaEssentia taps Incyte alum Eric Vogel as it eyes Besremi expansion
- Kaléo speaks up on allergy awareness to amplify patient stories
- Privacy and PetShops: Remarks at the Regulatory PETshop Series: Cryptographic Technologies and Financial Services Regulation
- NYC Health + Hospitals adds 2nd behavioral health housing site
- Mindfulness isn’t a perk anymore — it’s a workforce strategy
- With Elahere building steam, AbbVie nets FDA nod for another ImmunoGen cancer asset
- Hospitals again ask FTC, DOJ for exemption from expanded premerger notification filings
- Coalition for Health AI unveils governance playbooks for responsible AI adoption
- Amazon taps Roy Schoenberg to lead healthcare business as Neil Lindsay plans to step down
- Viridian, awaiting FDA decision, taps WuXi Bio in eye drug supply deal
- U.S. To Keep Ebola-Exposed Citizens In Kenya Under New Policy
- CAT on a Hot Tin Roof
- GLP-1 Meds May Help Slow the Spread of Certain Obesity-Related Cancers
- GoodRx launches subscription program for low-cost generic medications, telehealth services
- George Washington University locks deal to hand off debt-ridden physician practice to UHS
- Humana invests $83M in new Florida pharmacy distribution center
- As J&J separates from its orthopedics business, it's laying off 56 employees in New Jersey
- ASCO preview: With expectations jacked up, Akeso's ivonescimab to face scrutiny in high-stakes plenary
- An insider’s look at LillyDirect
- GLP-1 manufacturer CordenPharma strikes deal for peptide CDMO, lining up new production sites in US and China
- Weight-Loss Program Helps Women Battling Breast Cancer
- Younger U.S. Women of Color Face Rising Breast Cancer Deaths
- High Fitness Doesn’t Raise A-fib Risk In Young Men, Study Finds
- Cheaper, Alternative Health Plans Are Having A Moment, But Critics Urge Caution
- Ultrafine Wildfire Smoke Particles May Pose Serious Health Risks
- Nurse Convicted in Patient’s Death Turns Fatal Drug Error Into a Cautionary Tale
- Montana Hurries To Adopt Trump’s Medicaid Work Rules Amid Budget Woes
- Readers Address Drugged Driving, Suicide Prevention, Worker Shortages
- Amid policy and pricing headwinds, US healthcare and life sci faces 'vast field of opportunity': survey
- Amid policy and pricing headwinds, US healthcare and life sci faces 'vast field of opportunity': survey
- Biogen investigated by Italian regulator over multiple sclerosis ‘market abuse’ claims
- FDA delays ruling on AstraZeneca’s breast cancer drug after negative adcomm vote
- Eli Lilly wins argument over Noom’s GLP-1 dosing claims
- Remarks at the Stanford Rock Center for Corporate Governance
- Smart ring maker Oura files confidentially for IPO as consumer demand propels revenue growth
- Outlook moves toward potential US nod for thrice-snubbed eye drug with FDA appeal win
- JD Power: Cost pressures worsen member experience with commercial plans
- Trump Admin Bars Key U.S. Researchers From Global Virus Response Talk
- Listen to the Latest ‘KFF Health News Minute’
- As calls for COINS Act expansion grow, will new rules sweep up China biotech licensing?
- Radiopharmaceutical outfit Lantheus mulls potential $7B takeover by Curium: Bloomberg
- Everyone Has A Family Doc, But Can You Get An Appointment?
- Many U.S. College Students With Psychosis Are Not Receiving Treatment
- Antibiotics Won't Help Ease Asthma-Linked Wheezing in Kids
- Yoga Eases Insomnia And Anxiety In Cancer Survivors, Study Finds
- SK bioscience links up with Colombia to enable local production of varicella vaccine
- Dust Yields Clues to Viral Outbreaks, Study Finds
- 3 Medical Routines That Older People May Not Need
- Cheaper, Alternative Health Plans Are Having a Moment, but Critics Urge Caution
- Acting NIAID Chief Steps Down Amid Ebola, Hantavirus Concerns
- Sunscreen Confusion Puts More Americans At Risk For Melanoma
- 1 In 10 U.S. Surgeons Quit Practice, Study Warns Of Shortage
- Video Game Can Detect Depression In Minutes, Study Says
- Quitting Smoking Might Lower Your Dementia Risk
- Severe Asthma Often Comes With Other Serious Health Problems
- Efforts To Understand The Nation's Drugged Driving Problem Stall Under Trump
- RFK Jr. Fires Two Leaders Of Major U.S. Health Task Force
- Common Food Preservatives Linked to Major Heart Problems
- Migraine With Aura Linked To Middle-Age Stroke Risk
- Nicotine Vapes Triple Smokers' Odds Of Quitting Tobacco
- Fatty Liver Disease Increases Heart Attack Risk, Study Says
- Fixing Eligibility at the Point of Care: The Missing Link in Medical Device Reimbursement Integrity
- Fixing Eligibility at the Point of Care: The Missing Link in Medical Device Reimbursement Integrity
- The failure of the ‘usual suspects’ approach to life science recruitment
- The failure of the ‘usual suspects’ approach to life science recruitment
- Statement on Novel Exchange-Traded Funds (ETFs)
- Value, Focus, and the Future of MedTech: M&A and Divestitures are Rewriting the Strategic Playbook.
- Value, Focus, and the Future of MedTech: M&A and Divestitures are Rewriting the Strategic Playbook.
Child deaths from marijuana ingestion increase after each state legalization. Packaging marijuana edibles like popular foot items sure doesn't help.
Commission demands firms immediately change unfair and deceptive packaging
July 5, 2023
As part of its ongoing monitoring of health-related advertising claims, the Federal Trade Commission today sent cease and desist letters – jointly with the U.S. Food and Drug Administration (FDA) – to six companies currently marketing edible products containing Delta-8 tetrahydrocannabinol (THC) in packaging that is almost identical to many snacks and candy children eat, including Doritos tortilla chips, Cheetos cheese-flavored snacks, and Nerds candy.
“Marketing edible THC products that can be easily mistaken by children for regular foods is reckless and illegal,” said Samuel Levine, Director of the FTC’s Bureau of Consumer Protection. “Companies must ensure that their products are marketed safely and responsibly, especially when it comes to protecting the well-being of children.”
“Children are more vulnerable than adults to the effects of THC, with many who have been sickened and even hospitalized after eating ‘edibles’ containing it. That’s why we’re issuing warnings to several companies selling copycat food products containing delta-8 THC, which can be easily mistaken for popular foods that are appealing to children and can make it easy for a young child to ingest in very high doses without realizing it,” said Janet Woodcock, M.D., Principal Deputy Commissioner, FDA.
The agencies sent letters to the following companies: 1) Delta Munchies LLC (Los Angeles, California); 2) Exclusive Hemp Farms (Gilroy, California) and Etienne-DuBois, LLC/Oshipt (Henrico, Virginia); 3) North Carolina Hemp Exchange, LLC, dba NC Hemp Shoppe (Raleigh, North Carolina; 4) Dr. Smoke, LLC, aka Dr. S, LLC (Kansas City, Missouri); 5) Nikte's Wholesale, LLC (Albuquerque, New Mexico); and 6) The Haunted Vapor Room (Franklin, New Jersey).
According to the letters, after reviewing online marketing for Delta-8 THC products sold by the six companies, the FTC has determined that their advertising may violate Section 5 of the FTC Act, which prohibits unfair or deceptive acts in or affecting commerce, including practices that present unwarranted health or safety risks. The letters stress that preventing practices that present such risks, particularly to children, is one of the Commission’s highest priorities, and that imitating non-THC-containing food products that children consume is misleading.
The companies’ Delta-8 THC products mimic a range of food that appeal to children. Dr. Smoke, LLC, for example, sells THC-infused “Doritos” that are marketed in packaging that is nearly the same as that of Doritos Nacho Cheese Flavored Tortilla Chips (see graphic), including using the same red background, the use of the Doritos name and triangle logo, and the depiction of two tortilla chips in the same position. In addition, Dr. Smoke’s THC-infused “Cheetos” are sold in packaging that is nearly identical to that of Cheetos Crunchy Flamin’ Hot Cheese Flavored Snacks, right down to the use of the Chester Cheetah mascot.
Another company, The Haunted Vapor Room, sells Delta-8 THC products called Rope 500mg Delta-8 Nerds Candy and Medicated Dope Rope Bites (see graphic) that closely resemble Nerds Rope candy, with both comprising multi-colored crunchy candies attached to a gummy rope, and packaging for the former using what appears to be the Nerds candy mascot.
A third company, Delta Munchies, LLC, markets Delta-8 THC gummies that look like conventional gummy candies that are often consumed by children (see graphic). The brightly colored packaging includes images of the products in fruity and sour flavors that the FTC contends enhance their appeal to children and increases the likelihood that they will mistakenly eat them, thinking they are traditional gummy candies.
In the letters, the FTC demands the companies stop marketing edible Delta-8 THC products that imitate conventional foods using advertising or packaging that is likely to appeal to young children. The FTC also strongly encourages the sellers to review all of their marketing and product packaging for similar edible THC products, and to take swift action and steps to protect consumers, especially young children, from these products.
Finally, the FTC has asked each company to contact agency staff within 15 days to detail the specific actions it has taken to address the Commission’s concerns. The primary staff attorney on this matter is Christine DeLorme in the FTC’s Bureau of Consumer Protection.
Colorful graphics for specific products are shown in article photos.
Published yesterday by the Annals of Internal Medicine, a response to one of the pre-legalization claims: that medical marijuana access would help chronic pain patients transition from standard pain medications.
The article is eligible for CME Point-of-Care and MOC credits.
Full research accessible from the summary page: https://doi.org/10.7326/M23-0053
Original Research | 4 July 2023By Emma E. McGinty, PhD, Kayla N. Tormohlen, PhD, Nicholas J. Seewald, PhD, Mark C. Bicket, MD, PhD, Alexander D. McCourt, JD, PhD, Lainie Rutkow, JD, PhD, Sarah A. White, MS, and Elizabeth A. Stuart, PhDEffects of U.S. State Medical Cannabis Laws on Treatment of Chronic Noncancer Pain
Abstract
Background:
State medical cannabis laws may lead patients with chronic noncancer pain to substitute cannabis in place of prescription opioid or clinical guideline–concordant nonopioid prescription pain medications or procedures.
Objective:
To assess effects of state medical cannabis laws on receipt of prescription opioids, nonopioid prescription pain medications, and procedures for chronic noncancer pain.
Design:
Using data from 12 states that implemented medical cannabis laws and 17 comparison states, augmented synthetic control analyses estimated laws’ effects on receipt of chronic noncancer pain treatment, relative to predicted treatment receipt in the absence of the law.
Setting:
United States, 2010 to 2022.
Participants:
583 820 commercially insured adults with chronic noncancer pain.
Measurements:
Proportion of patients receiving any opioid prescription, nonopioid prescription pain medication, or procedure for chronic noncancer pain; volume of each treatment type; and mean days’ supply and mean morphine milligram equivalents per day of prescribed opioids, per patient in a given month.
Results:
In a given month during the first 3 years of law implementation, medical cannabis laws led to an average difference of 0.05 percentage points (95% CI, −0.12 to 0.21 percentage points), 0.05 percentage points (CI, −0.13 to 0.23 percentage points), and −0.17 percentage points (CI, −0.42 to 0.08 percentage points) in the proportion of patients receiving any opioid prescription, any nonopioid prescription pain medication, or any chronic pain procedure, respectively, relative to what we predict would have happened in that month had the law not been implemented.
Limitations:
This study used a strong nonexperimental design but relies on untestable assumptions involving parallel counterfactual trends. Statistical power is limited by the finite number of states. Results may not generalize to noncommercially insured populations.
Conclusion:
This study did not identify important effects of medical cannabis laws on receipt of opioid or nonopioid pain treatment among patients with chronic noncancer pain.
Primary Funding Source:
National Institute on Drug Abuse.
Get MHF Insights
News and tips for your healthcare freedom.
We never spam you. One-step unsubscribe.















